CRNAO Stock Overview
A clinical stage cancer immunotherapy and RNA therapeutics company.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Circio Holding ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr7.31 |
52 Week High | kr0 |
52 Week Low | kr0 |
Beta | 1.98 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -97.65% |
Change since IPO | -99.06% |
Recent News & Updates
Recent updates
Shareholder Returns
CRNAO | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | 1.9% | 0.5% |
1Y | n/a | -20.4% | 6.3% |
Return vs Industry: Insufficient data to determine how CRNAO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how CRNAO performed against the UK Market.
Price Volatility
CRNAO volatility | |
---|---|
CRNAO Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: CRNAO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CRNAO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 17 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
CRNAO fundamental statistics | |
---|---|
Market cap | kr44.92m |
Earnings (TTM) | -kr449.26m |
Revenue (TTM) | kr10.00m |
4.5x
P/S Ratio-0.1x
P/E RatioIs CRNAO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRNAO income statement (TTM) | |
---|---|
Revenue | kr10.00m |
Cost of Revenue | kr0 |
Gross Profit | kr10.00m |
Other Expenses | kr459.26m |
Earnings | -kr449.26m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | -59.00 |
Gross Margin | 100.00% |
Net Profit Margin | -4,491.69% |
Debt/Equity Ratio | -135.9% |
How did CRNAO perform over the long term?
See historical performance and comparison